ATLASCyclacel Pharmaceuticals (BGMS) earnings date: Nov 12, 2026
Cyclacel Pharmaceuticals (BGMS) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 12, 2026.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on BGMS
| Last price | $0.91 (+1.1%) |
|---|---|
| Normal 1-day range (±1σ) | ±5.9% |
| Earnings beat history | Beat the EPS estimate in 4 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Cyclacel Pharmaceuticals stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Cyclacel Pharmaceuticals reports on Nov 12, 2026. One email the day before, with ATLAS’s read on Cyclacel Pharmaceuticals. You can switch it off at any time.
Alert me before BGMS reportsFree to start. Creating an account takes under a minute.
Notify me when Cyclacel Pharmaceuticals reports
Track BGMS free Add Cyclacel Pharmaceuticals to a free ATLAS watchlist and see its next report date in one place.
BGMS earnings at a glance
| Next report (confirmed) | Thu, Nov 12, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| Last report | Apr 29, 2026 · Beat |
| Beat rate (last 5 reports) | 4 of 5 (80%) |
| Average EPS surprise | +36.7% |
| Average move around a report | ±3.8% (last 5) |
| Sector | Industrials · Building Products & Equipment |
Cyclacel Pharmaceuticals earnings history: last 5 reports
Cyclacel Pharmaceuticals last reported on Apr 29, 2026: EPS of $4.10 against an estimate of $3.69 (+11.1% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Apr 29, 2026 | $3.69 | $4.10 | +11.1% | Beat | +1.0% |
| Nov 12, 2024 | -$129.60 | -$43.20 | +66.7% | Beat | 0.0% |
| Aug 14, 2024 | -$344.40 | -$172.80 | +49.8% | Beat | -3.7% |
| May 14, 2024 | -$1,183.20 | -$544.80 | +54.0% | Beat | -3.9% |
| Mar 19, 2024 | -$1,524.00 | -$1,495.20 | +1.9% | In line | -10.4% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for BGMS
See the fair value, the probability range and the earnings history of Cyclacel Pharmaceuticals on its ATLAS page.
Cyclacel Pharmaceuticals (BGMS) stock analysisPlans from €3.99 a month.
Cyclacel Pharmaceuticals earnings: frequently asked questions
When does Cyclacel Pharmaceuticals (BGMS) report earnings?
Cyclacel Pharmaceuticals is scheduled to report on Thursday, November 12, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
How often does BGMS beat earnings estimates?
Of its last 5 reports with a recorded result, Cyclacel Pharmaceuticals beat the EPS estimate 4 times; the average surprise was +36.7%. Past results do not predict the next one.
How much does BGMS move around earnings?
Over its last 5 reports the stock moved an average of 3.8% (absolute, from the close before the report day to the close after it), and finished higher 1 of 5 times.
Did Cyclacel Pharmaceuticals beat earnings estimates last quarter?
Cyclacel Pharmaceuticals last reported on Apr 29, 2026: EPS of $4.10 against an estimate of $3.69 (+11.1% surprise), a beat.
How much does BGMS usually move in a day?
On a normal trading day the ATLAS model puts BGMS’s one-day range at about ±5.9%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 12, 2026
Educational information, not investment advice. Disclaimer